Skip to main content
ELUT
NASDAQ Life Sciences

Shareholders Approve 3 Million Share Increase for Equity Incentive Plan

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$0.95
Mkt Cap
$41.998M
52W Low
$0.5
52W High
$2.64
52W Position info
90% above low
Off High info
64% below high
Rel. Volume info
0.8× avg
Market data snapshot near publication time

ELUT sits 90% above its 52-week low of $0.5.

Summary

Elutia Inc. shareholders approved an amendment to the company's equity incentive plan, authorizing an additional 3 million shares for future awards, which represents significant potential dilution for existing shareholders.


Key Events · Corporate Governance and Compliance · ELUT

  • Equity Incentive Plan Expanded

    Shareholders approved an amendment to the 2020 Incentive Award Plan, authorizing an additional 3,000,000 shares for future equity awards. If all authorized shares were issued, dilution would be approximately 6.78%.

  • Plan Duration Extended

    The amendment also extends the annual increase of shares under the plan through January 1, 2036, and the overall termination date of the 2020 Plan.

  • Director Elections

    David Colpman and Kevin Rakin were elected as Class III directors to hold office until the 2029 annual meeting.

  • Auditor Ratification

    PricewaterhouseCoopers LLP was ratified as the independent registered public accounting firm for the year ending December 31, 2026.


Analysis · ELUT · Life Sciences

Elutia Inc. shareholders approved an amendment to the 2020 Incentive Award Plan, authorizing an additional 3,000,000 shares for future equity awards. This approval, following the proposal in April, means the company is now authorized to issue up to 3,000,000 more shares. If all these shares were issued, it would result in approximately 6.78% dilution for existing shareholders, a notable amount for a company facing ongoing financial challenges and increased cash burn.

At the time of this filing, ELUT was trading at $0.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $42M. The 52-week trading range was $0.50 to $2.64. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ELUT - Latest Insights

ELUT
Jul 16, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $0.9351
Real-time Price: $0.880 info
Change: -$0.0551 (-6%) info
Market Cap: $38.903M info
ELUT
May 15, 2026, 4:38 PM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $1.03
Real-time Price: $0.880 info
Change: -$0.150 (-15%) info
Market Cap: $38.903M info
ELUT
May 15, 2026, 4:31 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $1.03
Real-time Price: $0.880 info
Change: -$0.150 (-15%) info
Market Cap: $38.903M info
ELUT
May 14, 2026, 4:06 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $1.00
Real-time Price: $0.880 info
Change: -$0.120 (-12%) info
Market Cap: $38.903M info
ELUT
May 12, 2026, 4:12 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $1.05
Real-time Price: $0.880 info
Change: -$0.170 (-16%) info
Market Cap: $38.903M info